Molecular Formula | C15H19N5O |
Molar Mass | 285.34 |
Density | 1.272±0.06 g/cm3(Predicted) |
Appearance | powder |
Color | white to beige |
pKa | 13.03±0.50(Predicted) |
Storage Condition | room temp |
In vitro study | PF-06651600 is a new potent and selective inhibitor of JAK3, which is very effective in inhibiting γc factor signaling. In Vitro, PF-06651600 inhibits Th1 and Th17 cell differentiation and function. In total lymphocytes of human whole blood, PF-06651600 inhibiting STAT5 phosphorylation by IL-2, IL-4, IL-7, and IL-15, The IC50 was 244, 340, 407 and 266 nM, respectively. It also inhibits STAT3 phosphorylation by IL-21 with an IC50 of 355 nM. |
In vivo study | In the murine model of experimental autoimmune encephalomyelitis and in the rat adjuvant arthritis, PF-06651600 reduces the pathological features of the disease. PF-06651600 have suitable pharmacokinetic and pharmacodynamic properties in preclinical and clinical evaluations. The pharmacokinetic prediction of PF-06651600 in humans indicates that the blood clearance is about 5.6 mL/min/kg, the volume of distribution is 1.3 L/kg, and the oral bioavailability is 90%, the systemic Half-Life is 2 hours. |
biological activity | Ritlecitinib (PF-06651600) was a JAK3 selective inhibitor with an IC50 of 33.1 nM. There was no activity against JAK1, JAK2 and TYK2 (IC50 > 10 000 nM). |
Target | Value |
JAK3 (Cell-free assay) | 33.1 nM |